search
Back to results

A Study to Evaluate the Effects of the Neuroflo Device in People Who Have Had a Stroke (PAO)

Primary Purpose

Acute Stroke

Status
Withdrawn
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
NeuroFlo
Sponsored by
University of California, Los Angeles
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Stroke focused on measuring stroke, neuroflo, device, failure to recanalize

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥18 years
  • Acute cerebral ischemia due to occlusion of the internal carotid or middle cerebral artery
  • NIHSS 8-25 (inclusive)
  • Persistent arterial occlusion (defined as TICI 0 or 1) following failed mechanical revascularization (ref Table 2)
  • Able to undergo NeuroFlo treatment within 18 hours of symptom onset (or from last time known normal)
  • Informed consent from patient or legally authorized representative
  • Negative pregnancy test in females of child-bearing potential

Exclusion Criteria:

  • Etiology other than cerebral ischemia
  • Acute hypodense parenchymal lesion or effacement of cerebral sulci in more than 1/3 of the middle cerebral artery territory
  • Brainstem or cerebellar stroke
  • Systolic blood pressure (BP) >220 mm Hg, or diastolic (BP) >140 mm Hg that cannot be lowered with medical management
  • Any use of intravenous or intra-arterial thrombolytic medication
  • Known secured or unsecured cerebral aneurysm or vascular malformation on CTA or MRA or history thereof
  • Imaging evidence of current intracranial bleeding
  • History of intracerebral hemorrhage
  • Any aortic or femoral endovascular graft
  • Aortic surgery within 6 weeks prior to the time of enrollment
  • Known heparin sensitivity or allergy
  • Participation in another therapeutic/treatment research protocol
  • Any intracranial pathology interfering with the imaging assessments
  • Current congestive or decompensated heart failure
  • Known ejection fraction (EF) < 30% or evidence of NYHA Class IV or ACC/AHA Stage D heart failure within the past 3 months
  • Known or echo evidence of aortic regurgitation ≥ 3+
  • Myocardial infarction within last 3 months
  • Evidence of acute MI on ECG or by cardiac enzymes
  • Current or recent Class III or IV angina despite medical/surgical treatment
  • INR > 1.7
  • Platelet count < 100,000
  • Creatinine > 1.5 times local laboratory standard
  • Patients with cerebral arterial perforation or dissection due to attempted thrombectomy
  • Patients with complications of femoral artery cannulation
  • Patients with aortic diameter greater than 28 mm or smaller than 11 mm in diameter measured within 6 cm above and below the midpoint of the renal ostia (for 7Fr NeuroFlo Device)
  • Evidence of aortic aneurysm
  • High-grade iliac stenosis or vascular tortuosity that could prevent safe delivery and/or positioning of the NeuroFlo catheter

Sites / Locations

  • UCLA Medical Center

Outcomes

Primary Outcome Measures

Mortality and neurological deterioration at 5 days post treatment

Secondary Outcome Measures

Change in neurological status and adverse events from baseline through 30 days from treatment
Change in neurological status and adverse events from baseline through 90 days from treatment
Incidence of hemorrhagic transformation or other intracerebral bleeding at 5 days post treatment
Cerebral blood flow changes associated with device therapy assessed through multimodal MRI studies acquired at baseline and 3 hours post treatment obtained routinely at UCLA post IV or IA intervention in acute stroke patients

Full Information

First Posted
April 2, 2008
Last Updated
January 11, 2017
Sponsor
University of California, Los Angeles
Collaborators
CoAxia
search

1. Study Identification

Unique Protocol Identification Number
NCT00653536
Brief Title
A Study to Evaluate the Effects of the Neuroflo Device in People Who Have Had a Stroke
Acronym
PAO
Official Title
Feasibility and Safety of NeuroFlo™ in Patients With Persistent Arterial Occlusion (PAO) After Failed Mechanical Revascularization
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Withdrawn
Why Stopped
No Patients enrolled; sponsor not providing devices anymore
Study Start Date
March 2008 (undefined)
Primary Completion Date
January 2013 (Actual)
Study Completion Date
January 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Los Angeles
Collaborators
CoAxia

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Patients with acute ischemic stroke and persistent arterial occlusion following failed mechanical revascularization, who can undergo NeuroFlo treatment within 18 hours of last time symptom free, will be eligible for enrollment to assess the safety and feasibility of the NeuroFlo catheter in treating ischemic stroke patients with persistent arterial occlusion following attempted thrombectomy. The NeuroFlo catheter is designed to partially obstruct the abdominal descending aorta thereby increasing blood flow to the brain. Cerebral perfusion is improved by diverting more blood through vessels as well as by expansion of the collateral circulation. Improved regional perfusion leads to clinical improvement.
Detailed Description
Patients with occlusion of a proximal artery experience prompt diversion of flow through collaterals and retrograde perfusion of the occluded arterial tree. Collateral perfusion sustains the penumbra and may lessen stroke severity provided recanalization of the occluded artery occurs. Thrombectomy attempts to achieve recanalization of the occluded artery, but 36% of patients (90/252 in MERCI and MultiMERCI studies) experienced persistent arterial occlusion (PAO, defined as TICI flow 0-1). PAO following attempted thrombectomy was associated with high mortality, with 53% dead at 90 days. Of the survivors, only 5% achieved mRS of 0-2. At present, there are no therapies that have been shown to improve these risks. Data obtained from a clinically indicated CT at 24 hours will be used to monitor for safety. The safety endpoints for this study will be the proportion of patients who experience: Mortality and neurological deterioration (defined as an increase of ≥4 points on the NIHSS) at 5 days post treatment Change in neurological status and adverse events from baseline through 30 days from treatment Other endpoints include: Change in neurological status and adverse events from baseline through 90 days from treatment The incidence of hemorrhagic transformation or other intracerebral bleeding will be assessed at 5 days post treatment. Cerebral blood flow changes associated with device therapy will be assessed through multimodal CT or MRI studies acquired at baseline and 3 hours post treatment. Potential patient benefit will be assessed through collection of neurological indices (NIHSS etc.) at baseline, 24 hours post-procedure, day 5 (or discharge), 30 days and 90 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Stroke
Keywords
stroke, neuroflo, device, failure to recanalize

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
NeuroFlo
Intervention Description
The device will be inflated for 45 minutes in acute ischemic stroke patients who have failed mechanical recanalization.
Primary Outcome Measure Information:
Title
Mortality and neurological deterioration at 5 days post treatment
Time Frame
day 5
Secondary Outcome Measure Information:
Title
Change in neurological status and adverse events from baseline through 30 days from treatment
Time Frame
Day 30
Title
Change in neurological status and adverse events from baseline through 90 days from treatment
Time Frame
90 days
Title
Incidence of hemorrhagic transformation or other intracerebral bleeding at 5 days post treatment
Time Frame
day 5
Title
Cerebral blood flow changes associated with device therapy assessed through multimodal MRI studies acquired at baseline and 3 hours post treatment obtained routinely at UCLA post IV or IA intervention in acute stroke patients
Time Frame
3 hr and 24 hr

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥18 years Acute cerebral ischemia due to occlusion of the internal carotid or middle cerebral artery NIHSS 8-25 (inclusive) Persistent arterial occlusion (defined as TICI 0 or 1) following failed mechanical revascularization (ref Table 2) Able to undergo NeuroFlo treatment within 18 hours of symptom onset (or from last time known normal) Informed consent from patient or legally authorized representative Negative pregnancy test in females of child-bearing potential Exclusion Criteria: Etiology other than cerebral ischemia Acute hypodense parenchymal lesion or effacement of cerebral sulci in more than 1/3 of the middle cerebral artery territory Brainstem or cerebellar stroke Systolic blood pressure (BP) >220 mm Hg, or diastolic (BP) >140 mm Hg that cannot be lowered with medical management Any use of intravenous or intra-arterial thrombolytic medication Known secured or unsecured cerebral aneurysm or vascular malformation on CTA or MRA or history thereof Imaging evidence of current intracranial bleeding History of intracerebral hemorrhage Any aortic or femoral endovascular graft Aortic surgery within 6 weeks prior to the time of enrollment Known heparin sensitivity or allergy Participation in another therapeutic/treatment research protocol Any intracranial pathology interfering with the imaging assessments Current congestive or decompensated heart failure Known ejection fraction (EF) < 30% or evidence of NYHA Class IV or ACC/AHA Stage D heart failure within the past 3 months Known or echo evidence of aortic regurgitation ≥ 3+ Myocardial infarction within last 3 months Evidence of acute MI on ECG or by cardiac enzymes Current or recent Class III or IV angina despite medical/surgical treatment INR > 1.7 Platelet count < 100,000 Creatinine > 1.5 times local laboratory standard Patients with cerebral arterial perforation or dissection due to attempted thrombectomy Patients with complications of femoral artery cannulation Patients with aortic diameter greater than 28 mm or smaller than 11 mm in diameter measured within 6 cm above and below the midpoint of the renal ostia (for 7Fr NeuroFlo Device) Evidence of aortic aneurysm High-grade iliac stenosis or vascular tortuosity that could prevent safe delivery and/or positioning of the NeuroFlo catheter
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David S. Liebeskind, M.D.
Organizational Affiliation
University of California, Los Angeles
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sidney Starkman, M.D.
Organizational Affiliation
University of California, Los Angeles
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCLA Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Study to Evaluate the Effects of the Neuroflo Device in People Who Have Had a Stroke

We'll reach out to this number within 24 hrs